These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

152 related items for PubMed ID: 10972483

  • 1. Modulation of the pharmacokinetics of the antitumour agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in mice by thalidomide.
    Kestell P, Zhao L, Baguley BC, Palmer BD, Muller G, Paxton JW, Ching LM.
    Cancer Chemother Pharmacol; 2000; 46(2):135-41. PubMed ID: 10972483
    [Abstract] [Full Text] [Related]

  • 2. In vitro and in vivo kinetic interactions of the antitumour agent 5,6-dimethylxanthenone-4-acetic acid with thalidomide and diclofenac.
    Zhou S, Paxton JW, Kestell P, Tingle MD, Ching LM.
    Cancer Chemother Pharmacol; 2001 Apr; 47(4):319-26. PubMed ID: 11345648
    [Abstract] [Full Text] [Related]

  • 3. Modulation of thalidomide pharmacokinetics by cyclophosphamide or 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in mice: the role of tumour necrosis factor.
    Chung F, Wang LC, Kestell P, Baguley BC, Ching LM.
    Cancer Chemother Pharmacol; 2004 May; 53(5):377-83. PubMed ID: 15060740
    [Abstract] [Full Text] [Related]

  • 4. Thalidomide increases both intra-tumoural tumour necrosis factor-alpha production and anti-tumour activity in response to 5,6-dimethylxanthenone-4-acetic acid.
    Cao Z, Joseph WR, Browne WL, Mountjoy KG, Palmer BD, Baguley BC, Ching LM.
    Br J Cancer; 1999 May; 80(5-6):716-23. PubMed ID: 10360649
    [Abstract] [Full Text] [Related]

  • 5. A difference between the rat and mouse in the pharmacokinetic interaction of 5,6-dimethylxanthenone-4-acetic acid with thalidomide.
    Zhou S, Kestell P, Tingle MD, Ching LM, Paxton JW.
    Cancer Chemother Pharmacol; 2001 Jun; 47(6):541-4. PubMed ID: 11459209
    [Abstract] [Full Text] [Related]

  • 6. Suppression of serum tumour necrosis factor-alpha by thalidomide does not lead to reversal of tumour vascular collapse and anti-tumour activity of 5,6-dimethylxanthenone-4-acetic acid.
    Browne WL, Wilson WR, Baguley BC, Ching LM.
    Anticancer Res; 1998 Jun; 18(6A):4409-13. PubMed ID: 9891501
    [Abstract] [Full Text] [Related]

  • 7. Consequences of increased vascular permeability induced by treatment of mice with 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and thalidomide.
    Chung F, Liu J, Ching LM, Baguley BC.
    Cancer Chemother Pharmacol; 2008 Mar; 61(3):497-502. PubMed ID: 17473922
    [Abstract] [Full Text] [Related]

  • 8. Effects of the serotonin receptor antagonist cyproheptadine on the activity and pharmacokinetics of 5,6-dimethylxanthenone-4-acetic acid (DMXAA).
    Zhao L, Kestell P, Philpott M, Ching LM, Zhuang L, Baguley BC.
    Cancer Chemother Pharmacol; 2001 Jun; 47(6):491-7. PubMed ID: 11459201
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. 5,6-dimethylxanthenone-4-acetic acid (DMXAA): a new biological response modifier for cancer therapy.
    Zhou S, Kestell P, Baguley BC, Paxton JW.
    Invest New Drugs; 2002 Aug; 20(3):281-95. PubMed ID: 12201491
    [Abstract] [Full Text] [Related]

  • 11. Gender differences in the metabolism and pharmacokinetics of the experimental anticancer agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA).
    Zhou S, Kestell P, Tingle MD, Paxton JW.
    Cancer Chemother Pharmacol; 2002 Feb; 49(2):126-32. PubMed ID: 11862426
    [Abstract] [Full Text] [Related]

  • 12. Interaction of thalidomide, phthalimide analogues of thalidomide and pentoxifylline with the anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid: concomitant reduction of serum tumour necrosis factor-alpha and enhancement of anti-tumour activity.
    Ching LM, Browne WL, Tchernegovski R, Gregory T, Baguley BC, Palmer BD.
    Br J Cancer; 1998 Aug; 78(3):336-43. PubMed ID: 9703279
    [Abstract] [Full Text] [Related]

  • 13. Oral activity and pharmacokinetics of 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in mice.
    Zhao L, Kestell P, Ching LM, Baguley BC.
    Cancer Chemother Pharmacol; 2002 Jan; 49(1):20-6. PubMed ID: 11855749
    [Abstract] [Full Text] [Related]

  • 14. Marked potentiation of the antitumour activity of chemotherapeutic drugs by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA).
    Siim BG, Lee AE, Shalal-Zwain S, Pruijn FB, McKeage MJ, Wilson WR.
    Cancer Chemother Pharmacol; 2003 Jan; 51(1):43-52. PubMed ID: 12497205
    [Abstract] [Full Text] [Related]

  • 15. Pharmacokinetics of 5,6-dimethylxanthenone-4-acetic acid (AS1404), a novel vascular disrupting agent, in phase I clinical trial.
    Jameson MB, Baguley BC, Kestell P, Zhao L, Paxton JW, Thompson PI, Waller S, Cancer Research (UK) Phase I/II Trials Committee.
    Cancer Chemother Pharmacol; 2007 Apr; 59(5):681-7. PubMed ID: 17021822
    [Abstract] [Full Text] [Related]

  • 16. Mechanisms of enhancement of the antitumour activity of melphalan by the tumour-blood-flow inhibitor 5,6-dimethylxanthenone-4-acetic acid.
    Pruijn FB, van Daalen M, Holford NH, Wilson WR.
    Cancer Chemother Pharmacol; 1997 Apr; 39(6):541-6. PubMed ID: 9118467
    [Abstract] [Full Text] [Related]

  • 17. Interferon-inducible protein 10 induction and inhibition of angiogenesis in vivo by the antitumor agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA).
    Cao Z, Baguley BC, Ching LM.
    Cancer Res; 2001 Feb 15; 61(4):1517-21. PubMed ID: 11245459
    [Abstract] [Full Text] [Related]

  • 18. Identification and reactivity of the major metabolite (beta-1-glucuronide) of the anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in humans.
    Zhou SF, Paxton JW, Tingle MD, Kestell P, Jameson MB, Thompson PI, Baguley BC.
    Xenobiotica; 2001 May 15; 31(5):277-93. PubMed ID: 11491389
    [Abstract] [Full Text] [Related]

  • 19. Efficacy against subcutaneous or intracranial murine GL261 gliomas in relation to the concentration of the vascular-disrupting agent, 5,6-dimethylxanthenone-4-acetic acid (DMXAA), in the brain and plasma.
    Yung R, Seyfoddin V, Guise C, Tijono S, McGregor A, Connor B, Ching LM.
    Cancer Chemother Pharmacol; 2014 Mar 15; 73(3):639-49. PubMed ID: 24477604
    [Abstract] [Full Text] [Related]

  • 20. The antitumour activity of 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in TNF receptor-1 knockout mice.
    Zhao L, Ching LM, Kestell P, Baguley BC.
    Br J Cancer; 2002 Aug 12; 87(4):465-70. PubMed ID: 12177785
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.